Anabolic osteoporosis treatments are a class of bone-forming injectable therapies used for patients at high risk of fracture, and they sit apart from the antiresorptive drugs that make up most first-line osteoporosis care. An anabolic treatment for osteoporosis works by directly stimulating osteoblasts, the cells that lay down new bone, to increase bone mineral density and reduce fracture risk, often more rapidly than antiresorptive agents alone.
This article will explore how these anabolic drug treatments for osteoporosis work, who they are appropriate for, their documented side effects, how they compare with antiresorptive options, and what they typically cost.
Medica Depot compiles clinical background on categories such as anabolic osteoporosis treatments as a reference for prescribing clinicians and clinic owners. Clinicians who buy osteoporosis injection products for their practice can also review the broader category page before weighing anabolic options against antiresorptive ones.
Key Takeaways
- Anabolic osteoporosis treatments like teriparatide, abaloparatide, and romosozumab build new bone rather than merely slowing its loss, and are generally reserved for patients at high or very high fracture risk.
- Clinical trials have reported substantial reductions in vertebral fracture risk: up to 86% for abaloparatide, 73% for romosozumab, and 65% for teriparatide, each compared with placebo [1][3][4].
- Anabolic agents are used for a limited treatment window and are typically followed by an antiresorptive drug, such as a bisphosphonate, to preserve the bone density gains achieved [2].
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like anabolic osteoporosis treatments. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
What Are Anabolic Osteoporosis Treatments?
Osteoporosis develops when the normal balance between bone resorption (breakdown) and bone formation shifts toward loss, leaving bones porous and prone to fracture. Most osteoporosis medications, such as bisphosphonates, denosumab, and selective estrogen receptor modulators, are antiresorptive: they slow the osteoclasts that break down bone, and by doing so they indirectly preserve existing bone mass.
Anabolic osteoporosis treatments take a different route. Instead of slowing resorption, an anabolic treatment for osteoporosis directly stimulates osteoblast activity, driving new bone formation on both trabecular and cortical bone surfaces. Anabolic drugs can produce faster and more substantial gains in bone health for patients whose disease has progressed to a point where antiresorptive therapy alone is unlikely to be sufficient.
The three anabolic agents currently approved for osteoporosis in the United States are teriparatide (Forteo®), abaloparatide (Tymlos®), and romosozumab (Evenity®). Each has a distinct receptor target, but they share the same bone-building outcome.
Exploring How Anabolic Osteoporosis Treatments Work
The starting point for the mechanism is the parathyroid hormone (PTH) signaling pathway. Teriparatide is a recombinant form of the first 34 amino acids of human PTH. It binds to the PTH type 1 receptor on osteoblasts, activating intracellular signaling that increases osteoblast number and activity while suppressing their premature cell death [1]. Given as a once-daily injection, this intermittent exposure pattern allows teriparatide to favor bone formation over resorption.
Abaloparatide works through a closely related but distinct route. It is a synthetic analog of human parathyroid hormone-related protein (PTHrP), and its structure gives it a different binding profile on the same PTH1 receptor. Available data suggest this produces a more transient signal and a comparatively lower risk of hypercalcemia [3].
Romosozumab, the newest of the group, does not mimic PTH or PTHrP at all. It is a monoclonal antibody that inhibits sclerostin, a protein that normally restrains bone formation through the Wnt signaling pathway. Blocking sclerostin increases bone formation while also reducing bone resorption [4].
Antiresorptive agents such as risedronate slow bone turnover by binding to bone mineral and inhibiting osteoclasts. Anabolic agents for osteoporosis treatment, teriparatide and risedronate together illustrate the two ends of the mechanistic spectrum that clinicians work with when they sequence therapy.
Who Are Anabolic Treatments For? Patient Candidacy and High Fracture Risk
Anabolic agents are not typically first-line therapy. Current guidelines, including the 2020 American Association of Clinical Endocrinology/American College of Endocrinology (AACE/ACE) clinical practice guidelines, direct clinicians to reserve them for patients with osteoporosis who fall into a “very high” fracture-risk category [2].
That category includes patients with a recent fracture, multiple prior fractures, a fracture sustained while already on osteoporosis therapy, a T-score below −3.0, a history of injurious falls, or a FRAX-calculated 10-year fracture probability above defined thresholds [2].
In practice, this most often means postmenopausal women with low bone mineral density in postmenopausal women who have already sustained a fragility fracture, as well as men with hypogonadal or idiopathic osteoporosis and patients with glucocorticoid-induced bone loss.
For these patients at high risk of fracture, guidelines increasingly favor starting with an anabolic agent and following it with an antiresorptive drug. Beginning with an antiresorptive can blunt the bone-forming effect of the anabolic agent used afterward [2].
Possible Side Effects of Anabolic Therapy for Osteoporosis
The most common adverse events reported with teriparatide and abaloparatide include injection-site reactions, transient dizziness, leg cramps, nausea, and mild hypercalcemia. Both drugs also carry a caution about orthostatic hypotension shortly after the first few doses [1][3]. Both agents were originally approved with a boxed warning about osteosarcoma, based on findings in rats given very high, near-lifetime doses.
The FDA removed that boxed warning from teriparatide’s label in 2020, and from abaloparatide’s label in 2021, after years of post-marketing surveillance data showed no corresponding signal in humans. Alongside the 2020 update, the FDA also removed teriparatide’s two-year lifetime cap; use beyond two years may be considered for patients who remain at high fracture risk. Abaloparatide’s label, by contrast, continues to recommend against cumulative use beyond 24 months as a warning and precaution rather than a boxed warning [5].
Both agents remain contraindicated in patients with Paget’s disease of bone, unexplained elevated alkaline phosphatase, open growth plates, bone metastases or skeletal malignancies, or prior skeletal radiation [5].
Romosozumab’s safety profile looks different. Common reactions include arthralgia, headache, and injection-site pain. The label, however, carries a boxed warning: an increased rate of major adverse cardiovascular events was observed when it was compared head-to-head against a bisphosphonate in a large trial. As a result, romosozumab should not be started in patients who have had a heart attack or stroke within the preceding year [4].
Comparing Anabolic Treatments to Antiresorptive Options Like Bisphosphonates
Bisphosphonates such as alendronate and risedronate remain the most widely prescribed osteoporosis drugs because they are inexpensive, oral or infrequently dosed, and effective at reducing fracture risk for most patients.
Head-to-head and placebo-controlled data show that anabolic agents for osteoporosis treatment tend to produce larger, faster gains in bone mineral density and greater reductions in vertebral fracture risk, particularly for patients whose disease is already advanced [1][3][4]. The trade-off is higher cost, a daily or monthly injection burden, and a defined treatment window.
Because discontinuing an anabolic agent without follow-up therapy leads to a fairly rapid reversal of the bone gained, current practice calls for deliberate sequencing. An anabolic agent goes first in very-high-risk patients, followed immediately by an antiresorptive drug such as a bisphosphonate or denosumab to help lock in the density gains [2]. Starting with an antiresorptive and introducing an anabolic agent later tends to blunt the anabolic agent’s effect, since the antiresorptive suppresses the bone turnover that the anabolic agent depends on.
Determining what the safest injection for osteoporosis is[1] in a given patient depends on cardiovascular, gastrointestinal, and skeletal risk factors that vary across the injectable category, and those factors often shape whether an anabolic agent, an antiresorptive, or a sequenced combination is appropriate.
What Results Can Be Expected From Anabolic Osteoporosis Treatment?
Bone formation markers rise within the first month of anabolic therapy and typically peak within six months, well before bone resorption markers catch up. That pattern helps explain why these drugs produce measurable gains in bone health relatively quickly [1].
In the pivotal trial that established teriparatide’s efficacy, the 20-microgram daily dose reduced the relative risk of new vertebral fractures by 65% and non-vertebral fragility fractures by about one-third to one-half compared with placebo over a median of 21 months, alongside a 9-percentage-point increase in lumbar spine bone mineral density [1].
Abaloparatide’s ACTIVE trial reported an 86% reduction in vertebral fracture risk and a 43% reduction in non-vertebral fracture risk over 18 months versus placebo [3]. Dosed monthly, romosozumab produced a 73% reduction in vertebral fracture risk within just 12 months in the FRAME trial, which ranks among the fastest fracture-risk reductions reported for any osteoporosis therapy to date [4].
Treatment courses for anabolic osteoporosis treatments are time-limited. Teriparatide and abaloparatide are typically used for up to 18–24 months, and romosozumab for 12 months, after which patients transition to an antiresorptive agent to help preserve the gains made during the anabolic phase [2][5].
How Much Do Anabolic Osteoporosis Treatments Cost?
Cost is one of the most significant barriers to anabolic therapy. In the United States, list and retail prices for teriparatide, abaloparatide, and romosozumab have historically run into the thousands of dollars per month.
A single teriparatide pen can range from around $1,500 to several thousand dollars, depending on the pharmacy and any manufacturer or discount offers applied. Abaloparatide and romosozumab carry comparable monthly costs.
An independent cost-effectiveness review published by the Institute for Clinical and Economic Review (ICER) concluded that, at their original launch prices, none of the three anabolic osteoporosis treatments met standard cost-effectiveness thresholds relative to generic bisphosphonates.
Outside the United States, these agents are typically priced through national reimbursement or single-payer negotiations, which generally bring the effective cost well below U.S. list prices. National formularies in countries such as Australia, Germany, and Brazil have negotiated abaloparatide and romosozumab pricing using cost-minimization comparisons against each other and against teriparatide, rather than list-price benchmarks.
The availability of a lower-cost teriparatide biosimilar in the U.S. market has also begun to narrow out-of-pocket costs for that particular agent, though coverage and formulary placement still vary considerably by insurer. Our clients tell us this variability is one of the reasons anabolic therapy is planned so carefully, since a treatment window measured in months can be derailed if reimbursement changes mid-course.
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] Neer, R M et al. “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.” The New England journal of medicine vol. 344,19 (2001): 1434-41. doi:10.1056/NEJM200105103441904
[2] Camacho, Pauline M et al. “AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 26,Suppl 1 (2020): 1-46. doi:10.4158/GL-2020-0524SUPPL
[3] Miller, Paul D et al. “Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.” JAMA vol. 316,7 (2016): 722-33. doi:10.1001/jama.2016.11136
[4] Cosman, Felicia et al. “Romosozumab Treatment in Postmenopausal Women with Osteoporosis.” The New England journal of medicine vol. 375,16 (2016): 1532-1543. doi:10.1056/NEJMoa1607948
[5] Krege, John H et al. “Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.” JBMR plus vol. 6,9 e10665. 14 Aug. 2022, doi:10.1002/jbm4.10665
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
